Leishmania donovani, a protozoan parasite, causes a strong immunosuppression in a susceptible host and inflicts the fatal disease visceral leishmaniasis. Relatively high toxicity, low therapeutic inde
This study aimed to develop a novel nanotherapeutic approach by combining an interleukin-10 (IL-10) peptide antagonist with amphotericin B (AmB) to enhance antileishmanial efficacy while reducing cyto
IC50 and EC50 values of imipramine to recent antimony sensitive (BHU 777 and BHU 816) and antimony resistant (BHU 872, BHU 782, BHU 814 and BHU 575) clinical isolates of Leishmania donovani (LD) proma
BACKGROUND Treatment-refractory visceral leishmaniasis (VL) has become an important problem in many countries. OBJECTIVES We evaluated the antimony-resistance mechanisms of Leishmania infantum isola